Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies
Authors
Keywords
-
Journal
CLINICAL INFECTIOUS DISEASES
Volume 64, Issue 1, Pages 44-52
Publisher
Oxford University Press (OUP)
Online
2016-10-11
DOI
10.1093/cid/ciw676
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hepatitis C reinfection after sustained virological response
- (2016) Håvard Midgard et al. JOURNAL OF HEPATOLOGY
- Efficacy of Ledipasvir and Sofosbuvir, With or Without Ribavirin, for 12 Weeks in Patients With HCV Genotype 3 or 6 Infection
- (2015) Edward J. Gane et al. GASTROENTEROLOGY
- Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens
- (2015) David Wyles et al. HEPATOLOGY
- Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study
- (2015) Jean-Michel Molina et al. LANCET
- Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
- (2015) Anita Kohli et al. LANCET INFECTIOUS DISEASES
- Re-treatment of Chronic Hepatitis C Virus Genotype 1 Infection After Relapse
- (2014) Anu Osinusi et al. ANNALS OF INTERNAL MEDICINE
- Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials
- (2014) Evguenia S. Svarovskaia et al. CLINICAL INFECTIOUS DISEASES
- Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir
- (2014) Eric F. Donaldson et al. HEPATOLOGY
- Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
- (2014) Mark S. Sulkowski et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- O8 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY
- (2014) R. Esteban et al. JOURNAL OF HEPATOLOGY
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Earlier Sustained Virologic Response End Points for Regulatory Approval and Dose Selection of Hepatitis C Therapies
- (2013) Jianmeng Chen et al. GASTROENTEROLOGY
- Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon-free treatment in the SOUND-C2 study
- (2013) Stefan Zeuzem et al. HEPATOLOGY
- 848 HIGH CONCORDANCE OF SVR4, SVR12, AND SVR24 IN PATIENTS WITH HCV INFECTION WHO HAVE RECEIVED TREATMENT WITH SOFOSBUVIR
- (2013) E. Lawitz et al. JOURNAL OF HEPATOLOGY
- Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
- (2013) Kris V Kowdley et al. LANCET
- Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
- (2013) Eric Lawitz et al. LANCET
- Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial
- (2013) Eric Lawitz et al. LANCET INFECTIOUS DISEASES
- MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0
- (2013) Koichiro Tamura et al. MOLECULAR BIOLOGY AND EVOLUTION
- Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
- (2013) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
- (2013) Eric Lawitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus
- (2012) Angela M. Lam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: A randomized, 28-day, dose-ranging trial
- (2012) Maribel Rodriguez-Torres et al. JOURNAL OF HEPATOLOGY
- New Algorithms and Methods to Estimate Maximum-Likelihood Phylogenies: Assessing the Performance of PhyML 3.0
- (2010) Stéphane Guindon et al. SYSTEMATIC BIOLOGY
- Evidence of a Large, International Network of HCV Transmission in HIV-Positive Men Who Have Sex With Men
- (2009) Thijis van de Laar et al. GASTROENTEROLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now